Extrait

To evaluate long-term safety (primarily by recording adverse events including inhibitors), efficacy and patient acceptance of KOGENATE Bayer in home treatment either on prophylaxis or on demand. To evaluate both safety and efficacy with respect to lot variability, in particular regarding lot-groups formulated with or without fix between.

Critère d'inclusion

• Hemophilia A

Pays

• Austria
• Belgium
• Denmark
• France
• Greece
• Italy
• Netherlands
• Spain
• Sweden
• Switzerland

Liens

• ictrp
• nct